Weight-loss drug for fertility-sparing treatment of early uterine cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a weight-loss medication called semaglutide (Wegovy) combined with a hormonal intrauterine device (Mirena) for treating early-stage uterine cancer or precancerous changes in the uterus, while preserving fertility. The goal is to see if this combination can shrink or eliminate the abnormal cells, allowing patients to keep the option of having children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a body mass index (BMI) of 27 or higher
- Have a diagnosis of grade 1 endometrioid endometrial cancer (low-grade, early-stage) or atypical hyperplasia (precancerous changes) confirmed by biopsy
- For those with cancer, it must be stage 1A without spread beyond the uterus and no muscle invasion (confirmed by MRI or CT scan)
- Be in good overall health (ECOG performance status less than 2)
- Be interested in preserving fertility
- Be able to understand and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a weight-loss medication called semaglutide combined with a hormonal intrauterine device (IUD) can help treat early-stage endometrial cancer or precancerous changes, allowing patients who want to preserve fertility or avoid surgery to do so. The study also includes a structured weight loss program.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This study tests whether the medicine tirzepatide, which is used for weight loss, can help women with early-stage endometrial cancer or a pre-cancerous condition avoid or delay surgery. It combines taking tizepatide with a hormonal intrauterine device (Mirena) to try to shrink or stop the cancer from growing.
This trial tests whether semaglutide, a medication used for weight management, can improve the quality of embryos in women who are overweight or have obesity and are doing IVF. It aims to see if taking semaglutide before the IVF process helps make healthier embryos that can be frozen for later use.
This study observes how Wegovy works in everyday medical practice for people who are starting it for the first time. It will help doctors learn more about its real-life benefits and safety.
This trial compares a semaglutide injection to the already-approved weight loss drug Wegovy in Chinese adults with obesity. It aims to see if the new option works just as well to help people lose weight.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.